|
KMID : 1143420160090370727
|
|
Public Health Weekly Report
2016 Volume.9 No. 37 p.727 ~ p.732
|
|
|
Trend in Human Therapeutic MERS-CoV Antibody Development
|
|
Lee Han-Saem
Kim Sung-Soon
|
|
|
Abstract
|
|
|
BACKGROUND: After the Middle East respiratory syndrome coronavirus (MERS-Cov) outbreak in South Korea in 2015, the development of safe and effective therapeutics for the infection has become an urgent need. Although the several treatment methods using antiviral drugs and recombinant interferons were used to treat MERS-CoV-infected patients, adverse effects of those treatments were reported. Those treatments were known to be ineffective to the MERS-CoV patients suffering from severe pneumonia.
SUMMARY: Recently, it was found out that the human monoclonal antibodies emerged as safe and effective therapeutic molecules to block the severity of infectious diseases. As molecular technology was developed rapidly, the various advanced techniques expedited the generation of monoclonal antibodies as bio-drugs. Hence, we have been introducing the molecular techniques and researches for the development of human MERS-CoV antibodies.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|